Wikipedia -WSS

Wikipedia

author：explore 2025-09-06 10:14:01 Page View：9444

Bristol Myers Squibb sign — Courtesy Bristol Myers Squibb

Bristol Myers Squibb will pay $4.1 billion for RayzeBio, the companies said Tuesday, buying into the fast-growing field of using targeted doses of radiation to treat cancer.

RayzeBio, which raised about $350 million in a September initial public offering, is working in radiopharmaceuticals, which pair the tumor-killing power of radiation with the precision of targeted cancer therapies. The company is currently running a pivotal trial of its most advanced drug, RYZ101, in neuroendocrine cancer and has a pipeline of treatments for kidney, liver, and other cancers.

Bristol Myers will pay $62.50 in cash per share of RayzeBio, a roughly 115% premium to the company’s recent trading and more than triple the company’s IPO price.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： BMI, flaws aside, is found to be useful estimate of body fat in youth
Next article： Malaria cases in Florida and Texas: Here’s what you need to know

leisure time

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

AdobeSometimes,anappleadayreallyisjustwhatthedoctorordered.Andforthepastseveralyears,organizationsli

Shifting the focus from loneliness to social health

AdobeIt’sbeenoneyearsincetheU.S.surgeongeneralissuedanationalwarningaboutanepidemicofloneliness.Othe

Tori Bowie and the unacceptable rates of Black maternal death

AlastairGrant/APThehorrorstoriesofBlackwomendyingorcomingclosetodeathinchildbirthneverseemtostopcomi

Vaccine advisory panel ACIP left half staffed by HHS

ACIP,normallya15-memberpanel,haseightvacancies,andfourmorecomingsoon.Whyhasn'tHHSsignedoffontheCDC's